Seattle Genetics (SGEN.O) said it would receive $208 million from Pfizer Inc (PFE.N) for giving the world's biggest drugmaker the rights to utilize its antibody technology to treat a single cancer target. Seattle Genetics, which has signed ten such deals so far, said it would receive $8 million upfront and over $200 million in milestone payments. Its new partner Pfizer will be responsible for research, product development, manufacturing and commercialization of products, Seattle said in a statement.
Source
